This could open a gate toward new combined modalities in CRC therapies, especially in view of the emerging recent data about the inhibition of DDR1 kinase activity with nilotinib by reducing the β-catenin pathway [17]. The gene discussed is DDR1; the disease is colorectal carcinoma.